• sense clinically
  • think mechanistically
  • act interdisciplinarily
  • treat innovatively

Prof. Dr. med. Lars Bullinger

Director of the Medical Department
Division of Hematology, Oncology, and Tumor Immunology
Charité - Universitätsmedizin Berlin
Augustenburger Platz 1
13353 Berlin
Tel: +49 30 450 553 111
Fax: +49 30 450 553 914

Email: lars.bullinger@charite.de

https://haema-onko-cvk.charite.de/metas/person/person/address_detail/bullinger/

University Education

  • 1992-1997 Heidelberg Medical School, Heidelberg, Germany
  • 1998 Baylor College of Medicine, Houston, and Duke University, Durham, USA
  • 1999 MD, Heidelberg Medical School 2000 Dr. med. (University of Heidelberg)
  • 2008 Habilitation (University of Ulm) 2011 Assistant Prof. (apl. Professor), Internal Medicine (University of Ulm)
  • 2016 Associate Prof. (Univ. Prof., W3), Personalized Medicine (University of Ulm)
  • 2017 Full Professor (Univ. Prof., W3), Hematology / Oncology (Charité Berlin)

Professional Experience (selection)

  • 2010 Sabbatical in the Department of Pediatric Oncology (Prof. S. A. Armstrong), Dana Farber Cancer Institute, Harvard Medical School, MA, USA
  • 2011-2017 Attending Physician, Department of Internal Medicine III (Prof. H. Döhner), University Hospital of Ulm, Ulm, Germany
  • 2013-2017 Head of the Oncology Section of the Department of Internal Medicine III (Prof. H. Döhner), University Hospital of Ulm, Ulm, Germany
  • 2016-2017 Executive deputy director, Center of Internal Medicine; University Hospital of Ulm, Germany
  • 2016-2017 Professor for Personalized Medicine (W3), Medical Faculty University of Ulm, Germany
  • Since 2017 Director of the Department of Hematology, Oncology and Tumorimmunology (CVK), Charité University Medicine, Berlin, Germany

Research Fields

Our lab is committed to unravelling the genomic, epigenomic and transcriptomic changes leading up to and driving acute myeloid leukemia (AML) and other hematological malignancies. To this end, we employ massively parallelized next-generation sequencing (NGS) technologies, from Illumina and Oxford nanopore, to compare patient-derived primary tumor and matched control samples. Data analysis is developed and performed in-house by our own small team of bioinformaticians; findings of interest are followed up by functional validation in the lab. With close ties to the clinic, we are thus able to connect bench and bedside with our research in a dynamic exchange between dry in-silico and hands-on wet lab work. We are also well connected internationally and, for example, heavily involved in large cooperative projects such as SyTASC, SYNtherapy, and HARMONY.

haema-onko-cvk.charite.de/forschung/arbeitsgruppen/ag_bullinger/

Most important Awards, Grants or Scientific Achievements

  • 1998 DAAD scholarship
  • 2002-2003 DFG research scholarship
  • 2005 Franziska Kolb award for leukemia research
  • 2011-2014 Heisenberg scholarship (DFG)
  • 2015 Heisenberg Professor (DFG)

Selected References